A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2019
At a glance
- Drugs CGM 097 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Mar 2019 Planned End Date changed from 9 Jan 2019 to 19 Dec 2019.
- 28 Mar 2019 Planned primary completion date changed from 9 Jan 2019 to 18 Dec 2019.
- 05 Jun 2018 Planned End Date changed from 17 Jun 2018 to 9 Jan 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History